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Abstract
Background: Adverse drug reactions (ADRs) are now recognized as an important cause of
hospital admissions, with a proportion ranging from 0.9–7.9%. They also constitute a significant
economic burden. We thus aimed at determining the prevalence and the economic burden of
ADRs presenting to Medical Emergency Department (ED) of a tertiary referral center in India
Methods: A prospective, observational study of adult patients carried out over a 6 week period
in 2005. The prevalence of ADRs, their economic burden from the hospital perspective, severity,
and preventability were assessed using standard criteria.
Results: A total 6899 patients presented during the study period. Of these, 2046 were admitted
for various reasons. A total of 265/6899 patients had ADRs (3.84 %). A total of 141/265 was
admitted due to ADsR, and thus ADRs as a cause of admissions were 6.89% of total admissions. A
majority (74.71%) were found to be of moderate severity. The most common ADRs were anti-
tubercular drug induced hepatotoxicity, warfarin toxicity and chloroquine induced gastritis. The
median duration of hospitalization was 5 days [95% CI 5.37, 7.11], and the average hospitalization
cost incurred per patient was INR 6197/- (USD 150). Of total ADRs, 59.62% (158/265) were found
to be either definitely or potentially avoidable.
Conclusion: The study shows that ADRs leading to hospitalization are frequent and constitute a
significant economic burden. Training of patients and prescribers may lead to a reduction in
hospitalization due to avoidable ADRs and thus lessen their economic burden.
Background
Adverse Drug Reactions (ADRs) are a major problem
worldwide and are one of the leading causes of mortality
and morbidity in health care facilities worldwide. A land-
mark study by Lazarou et al found ADRs to be the fourth
to sixth leading cause of death in the United States and
serious ADRs accounted for 6.7% of hospitalized admis-
sions. [1] A study by Ramesh et al in India carried out in a
tertiary referral center in South India showed that admis-
sions due to ADRs accounted for 0.7% of total admissions
and deaths due to ADRs accounted for 1.8% of total
ADRs. [2] The study also showed that the average cost
involved in treating these ADRs was INR 690/- (USD 15$)
per patient. Many such studies were either limited to indi-
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vidual units such as geriatric care [3,4] or were carried out
retrospectively [5,6]. In India, very few studies have
looked at ADRs as the cause of hospital admissions and
fewer still have looked at costs associated with ADRs. The
present study was envisaged to evaluate the prevalence of
patients presenting with ADRs to the Emergency Depart-
ment (ED) and to assess the causality, avoidability, and
severity. The study also aimed determining the economic
burden of ADRs from a hospital perspective.
Methods
The study protocol was approved by the institutional eth-
ics committee and the study was conducted from 1st May
to 15th June 2005 at the King Edward Memorial hospital,
an 1800 bedded tertiary referral center in Mumbai (Bom-
bay), India. The study was observational, non-interven-
tional, prospective and carried out in the medicine
division of the ED. Only adults (age > 18 years) were stud-
ied. The 24 hours emergency department of the hospital is
manned by senior lecturers who work in 8 hour shifts for
a three month tenure. They work under the supervision of
author 4. They form the first contact point for all patients.
For the present study, authors 1, 2 and 3 each worked 8
hour shifts by rotation alongside and assessed the ADRs
with them. Decision making as to whether or not an event
was causally related to a drug was made either by the 3
senior lecturers or author 4, all of whom have a postgrad-
uate degree in internal medicine and several years of expe-
rience working in the ED. While no structured
questionnaire was used for the present study, drug intake
formed an important component of history taking.
The definition of an ADR used was the one developed by
the World Health Organization [7]. The assessment of
causality was then performed for all the cases using the
Naranjo's algorithm [8] The severity of ADRs was deter-
mined by using the Modified Hartwig and Seigel scale [9].
The avoidability of ADRs was assessed by using the defini-
tions developed by Hallas et al [10] and ADRs were classi-
fied as definitely avoidable, possible avoidable and
unavoidable. All the above scales were used at any given
time by one senior lecturer only in view of their work tim-
ings. The methodology used was identical to the study car-
ried out by Pirmohamed et al that looked at ADRs as the
cause of admissions to hospitals in the United Kingdom.
[11] Whenever ADRs were the cause of admissions, the
total length of hospital stay was also recorded. The eco-
nomic burden to the hospital was then calculated by the
product of total number of admission days of all patients
admitted with the ADR and hospital expenditure per day.
Statistical Analysis
Descriptive statistics were primarily used and data
expressed as percentages and medians with 95% CIs.
Results
Demographic Data
During the 6 week study period, 6899 patients presented
to the Emergency Department. Of these, 2046 patients
were admitted for various reasons. A total of 265/6899
patients had 340 ADRs giving 3.84% as the percentage of
patients presenting to the ED with an ADR. A total of 141/
265 were admitted due to the ADR, and thus ADRs as a
cause of admissions were 141/2046 or 6.89% of total
admissions. The mean age of patients with ADRs was 40
years. Using the Naranjo's algorithm, of the total 340
ADRs it was found that 13 were definite, 292 were proba-
ble, and 35 were possible. No change in causality was
made after the initial assessment.
Severity
Using the Modified Hartwig et al criteria, it was seen that
49/265 (18.49%) patients had mild ADRs while 198/265
(74.71%) patients had ADRs of moderate severity and 18/
265 (6.79%) patients had severe ADRs. Thus a majority of
the ADRs detected were of moderate severity.
Avoidability
It was seen that 27 (10.19%) ADRs were definitely avoid-
able while 131 (49.43%) were possible avoidable and 107
(40.37%) were unavoidable. Thus, 59.62% (158/265) of
the total ADRs detected were found to be either definitely
or potentially avoidable.
Economic burden to the Hospital
The median hospital stay of patients with ADRs was 5
days (95% CI 5.37 to 7.11) and the average cost per
patient hospitalized with an ADR was INR 6,197/- (USD
150$). The total cost to the hospital due to hospitalization
of patients presenting with ADRs over the 6 week period
in the emergency department was INR 11,21,657/- (USD
27358).
Commonest ADRs, Drug Classes and Organ Systems (table 
1)
Anti-tubercular drug induced hepatitis, warfarin toxicity
and chloroquine induced gastritis were the commonest
ADRs seen accounting for 28, 24, and 22 ADRs respec-
tively out of the 265 ADRs. Among the drug classes it was
found that anti-tubercular agents were most commonly
implicated and accounted for 52 ADRs. Of these 52, there
were 9 severe, 42 moderate and 1 was a mild ADR. This
was followed by antiepileptic and anti-malarial agents
accounting for 36 ADRs and 30 ADRs respectively. Of
ADRs caused by antiepileptic drugs, there were 3 severe,
27 moderate and 6 mild ADRs. The severity assessment of
ADRs caused by anti-malarial agents showed that there
were 17 mild, 13 moderate and no severe ADRs.BMC Clinical Pharmacology 2007, 7:8 http://www.biomedcentral.com/1472-6904/7/8
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Deaths due to ADRs
These were hepatotoxicity due to anti tubercular drugs
(9), intracranial bleed due to warfarin (5), bone marrow
suppression due to phenytoin (1), and hypoglycemia due
to glibenclamide (2). The overall incidence of fatal ADRs
was 0.83% (17/2046) of hospitalized patients.
Discussion and Conclusion
The present prospective study carried out over a 6 week
period in a tertiary referral center among adult patients
showed that ADRs accounted for 3.84% (265/6899) of
patients presenting to the ED. Of these 141 were admitted
and thus 53.21 % (141/265) of total patients presenting
to the ED with ADRs were hospitalized. At an average cost
of USD 150 per patient hospitalized, they also constituted
a significant economic burden.
Several studies carried out in different parts of the world
have also yielded more or less similar results. The present
study modeled on the study by Pirmohamed et al done in
the United Kingdom had similar findings. [11] Their
study found 6.5% of ADRs causing admissions, as against
our finding of 6.89%. Dormann et al evaluated the eco-
nomic impact of readmissions and ADRs in internal med-
icine. [12] ADRs were found to cause hospitalization in
6.2% of first admissions and in 4.2% of readmissions. Fat-
tinger et al in their study in two Swiss departments of
internal medicine found ADRs to account for 3.3% of all
hospitalizations. [13] In the present study, the mean dura-
tion of hospitalization ranged from 5–7 days while Pir-
mohamed found the hospitalization to range from 4–18
days. The latter also found a larger number of definite and
potentially avoidable ADRs compared to our study (72%
Table 1: Table depicting drugs and nature of adverse events seen during the study
Drug Class/Drug NO. (%) OF ADRS Individual drugs Adverse Event
Anti tubercular agents (AKT) 52 HRZ (35), AKT (7), Rifampin (4), Ethambutol (2), 
Pyrazinamide (2) Streptomycin (1), Isoniazid(1),
Thrombocytopenia, Hepatitis, Hepatic encephalopathy, 
Retro bulbar neuritis, Cholestatic jaundice, Erythema 
multiforme, Vestibular toxicity, Gastritis, Abdominal/
Respiratory/Flu like syndrome, Hypersensitivity 
reaction, Psychosis, Peripheral neuropathy, 
dysglycemia
Antiepileptics 36 Phenytoin(24), Valproate (5), Phenobarbiturate(4) 
carbamazepine (3)
Erythema multiforme, Symptomatic toxic 
carbamazepine/phenytoin/valproate levels with 
cerebellar signs
Antimalarials 30 Chloroquine (29), Sulfadoxine-pyrimethamine (1) Gastritis, Giddiness, Erthyema multiforme, Psychosis, 
Hypersensitivity reactions, Hypotension
Anticoagulants 25 Warfarin (24), Heparin (1) GI bleeding, haematuria, high INR, Intracranial bleed
Oral hypoglycemic agents (OHA) 16 Glibenclamide (10), Glyburide (6) Hypoglycemia, seizures,
NSAIDS 14 Paracetamol (6), Aspirin (3), Ibuprofen (1), Etoricoxib 
(1), Nimesulide (2), Diclofenac (1)
Hypersensitivity reaction, Gastritis, mucosal damage, 
Hematuria, (Etoricoxib) potentiates OHA induced 
Hypoglycemia, ARF on CRF, Thrombocytopenia
Antihypertensives 10 Atenolol (4), ACE inhibitors (2), Losartan (2), 
Clonidine (1), Isosorbide dinitrate (1)
Hypotension, Hypersensitivity reaction, AV block, 
Bradycardia, Hyperkalemia, Missed dose of clonidine 
leading to rebound hypertension, dry mouth
Cytotoxic drugs 9 Methotrexate (3), 5-Fluorouracil (2), Cisplatin (1), 
Etoposide (1), Paclitaxel (1), Chemo (1)
Bone marrow suppression (with opportunistic 
infection), Nephrotoxicity, Liver damage, GI mucositis, 
Anorexia, Myelodysplastic syndrome, Alopecia, 
Hyperuricemia, Abdominal pain, Neutropenia
Steroids 9 Prednisolone (7), Betamethasone (2) Gastritis, Hypertension, Hyperglycemia, Mania, Fragile 
skin, Facial puffiness, Osteoporosis, Opportunistic 
infections
Insulin 8 Humulin70/30 (8) Hypoglycemia, Erythema/swelling/stinging at injection 
site
Digoxin 8 -- Symptomatic toxic digoxin levels
Fluoroquinolones 8 Ciprofloxacin(4), Ofloxacin (2) Gatifloxacin (2) Complex partial seizures, Peripheral neuropathy, 
Dystonia, Hypersensitivity reaction, tendinitis, 
dysguesia
B lactam antibiotics 8 Amoxicillin(3), Ampicillin(2), Cefadroxil (1), 
Ceftriaxone (1), Ceftazidime (1)
Hypersensitivity reaction, Fixed drug eruptions, 
Diarrhea, muscle spasm, Generalized tonic-clonic 
seizure
Antiretrovirals 4 Efavirenz (2), Stavudine (1), Zidovudine (1) Metabolic acidosis, Drowsiness, hypokalemia, 
Peripheral neuropathy
Benzodiazepines 4 Chlordiazepoxide (2), Diazepam (2) Increased appetite and weight gain, Drowsiness, 
Ataxia, Amnesia, Vertigo
Bronchodilators 4 Salbutamol (3), Theophylline (1) Tremors
Haematinics 3 Ferrous fumarate(2) Ferrous sulfate (1) Epigastric pain, Heart burn, Vomiting, Metallic taste in 
mouth
Fibrinolytics 2 Urokinase (2) Hypotension, AV block
Miscellaneous 15 Metronidazole (1) Nicotinic acid (1) Fluconazole (1) 
Ethamsylate (1) Amitriptyline (1) Cotrimoxazole (1) 
Oxybutinin HCl (1) Dextropropoxy- phene (1) 
Urograffin (1) Amikacin (1) Benzthiazide (1) 
Amiodarone (1) Levodopa (1) Alendronate (1) 
Clozapine (1)
Gastritis Facial flush, Hypersensitivity reaction (4) 
Thrombocytopenia, dry mouth Perioral tingling 
numbness, Carpopedal spasm, Cochlear toxicity 
Muscle Cramps, Paresthesias raised liver functions 
Peak dose dyskinesias Esophagitis, constipation, seizureBMC Clinical Pharmacology 2007, 7:8 http://www.biomedcentral.com/1472-6904/7/8
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versus 59.62%). The study by Dormann found 44.3% of
ADRs to be preventable using the Schumock algorithm.
A comparison of deaths due to ADRs showed that while
we had 0.83% of hospitalized patients dying because of
ADRs, the study by Pirmohamed had 0.15% of hospital-
ized patients dying of ADRs. The study by Lazarou had
0.14% deaths that could be attributed to ADR related
admissions. These differences could perhaps be due to the
type of hospital, nature of disease and thus drugs pre-
scribed and perhaps inter country differences in suscepti-
bility.
The drawbacks of our study include the short duration (6
weeks), restriction to the medicine ED only; identification
of ADRs by one senior physician only at any given time
(who was on duty during rotation shifts in the ED),
restriction of the study only to adults and calculation of
costs based on duration of hospitalization only, which
could give an underestimate of the costs associated with
treating ADRs. Causality assessment was done at the point
of presentation to the ED and was not changed subse-
quently. Thus 35 "possible" ADRs where other factors
could account for the reaction were also included in the
final analysis. Also, causality assessment was done inde-
pendently by physicians on duty and their assessments
may not have been similar to one another. [14]
A similar study by Sanchez Cuervo et al, albeit retrospec-
tive and carried out over a 1 year period in Spain showed
some differences among the type of drugs causing ADRs in
the hospital's ED [15] While we found anti-tubercular
drug induced hepatotoxicity, chloroquine gastritis and
warfarin toxicity to be the common ADRs, they found
insulins, diuretics, digoxin and oral anti diabetics to be
the common causes of ADRs. For a country like India anti
tubercular toxicity could have additional ramifications
like the problem of multi drug resistance and exposure to
potentially more toxic second-line agents. Wu et al evalu-
ated outpatient ADRs leading to hospitalization and
found that anti-diabetics, anti-convulsants, anti-coagu-
lants, beta blockers and ACE inhibitors to be the common
causes of ADRs. [16] Both studies also found that ADRs
occurred in older patients, while we found the mean age
of patients with ADRs in our study to be 40 years.
Ayani I et al studied the economic burden in Spain of the
minimum direct costs to the public health system of diag-
nosing and treating patients in an ED with a suspected
ADR using the WHO definition of an ADR in a single
month. The cost amounted to 42,732 Ecus and consider-
ing that 40% of ADRs were avoidable, they proposed that
if pharmacovigilance activities included cost analysis, sig-
nificant savings would result. [17] The study by Wu et al
calculated the mean cost of treating an ADR per patient to
be USD 9491 with 50% of this cost being the hospitaliza-
tion or room charges alone. We included in our study the
hospitalization or room/bed charges only as we decided
to restrict the economic perspective to the hospital only.
Our hospital being a public hospital caters to the lower
socio-economic strata and hence costs would be different
from that of a private hospital. If we assume that similar
to the study by Wu et al, these represent only 50% of the
total costs, the economic burden of ADRs would be con-
siderable. Also, we found approximately 59.62% of ADRs
in our study to be avoidable or potentially avoidable. This
is similar to the findings of a meta-analysis where the rate
of preventable ADRs was found to be 59% (inter quartile
range 50–73%). [18] If these are minimized, it would lead
to considerable savings.
In conclusion, ADRs are an important cause of visits to the
hospital emergency department as well as an important
cause of admission and thus a significant economic bur-
den. It is likely that many of them particularly the avoida-
ble and potentially avoidable ones may be minimized by
patient and physician education and better prescribing
practices and thus lead to considerable cost savings.
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